Ken Griffin Cue Biopharma, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.45 - $1.08 $3,825 - $9,180	-8,500 Reduced 76.58%	2,600 $1,000
Q2 2024 Aug 14, 2024	BUY	$1.24 - $2.18 $5,952 - $10,464	4,800 Added 76.19%	11,100 $13,000
Q1 2024 May 15, 2024	BUY	$1.77 - $3.09 $8,673 - $15,141	4,900 Added 350.0%	6,300 $11,000
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.1 $10,320 - $18,600	-6,000 Reduced 81.08%	1,400 $3,000
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $2,007 - $4,221	900 Added 13.85%	7,400 $17,000
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $12,440 - $19,640	4,000 Added 160.0%	6,500 $23,000
Q1 2023 May 15, 2023	BUY	$2.41 - $3.74 $241 - $374	100 Added 4.17%	2,500 $8,000
Q4 2022 Feb 14, 2023	BUY	$2.39 - $3.95 $5,736 - $9,480	2,400 New	2,400 $6,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $43.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.